(redirected from Glucotrol xl)
Also found in: Dictionary, Thesaurus.
Related to Glucotrol xl: glipizide


a sulfonylurea used as a hypoglycemic in patients with type 2 diabetes mellitus whose blood glucose cannot be controlled by diet and exercise alone; administered orally.


Glibenese (UK), Glucotrol, Glucotrol XL, Minodiab (UK)

Pharmacologic class: Sulfonylurea

Therapeutic class: Hypoglycemic

Pregnancy risk category C


Lowers blood glucose level by stimulating insulin release from pancreas, increasing insulin sensitivity at receptor sites, and decreasing hepatic glucose production. Also increases peripheral tissue sensitivity to insulin and causes mild diuresis.


Tablets: 5 mg, 10 mg

Tablets (extended-release): 5 mg, 10 mg

Indications and dosages

To control blood glucose in type 2 (non-insulin-dependent) diabetes mellitus in patients who have some pancreatic function and don't respond to diet therapy

Adults: 5 mg/day P.O. initially, increased as needed after several days (range is 2.5 to 40 mg/day). Give extended-release tablet once daily; maximum dosage is 20 mg/day. Give daily dosage above 15 mg in two divided doses.

Conversion from insulin therapy

Adults: With insulin dosage above 20 units/day, start with usual glipizide dosage and reduce insulin dosage by 50%. With insulin dosage of 20 units/day or less, insulin may be discontinued when glipizide therapy starts.

Dosage adjustment

• Hepatic or renal impairment
• Elderly patients


• Hypersensitivity to drug
• Severe renal, hepatic, thyroid, or other endocrine disease
• Uncontrolled infection, serious burns, or trauma
• Diabetic ketoacidosis
• Pregnancy or breastfeeding


Use cautiously in:
• mild to moderate hepatic, renal, or cardiovascular disease; impaired thyroid, pituitary, or adrenal function
• elderly patients.


• Check baseline creatinine level for normal renal function before giving first dose.
• Give daily dose (extended-release) at breakfast.
• Administer immediate-release tablets 30 minutes before a meal (preferably breakfast). If patient takes two daily doses, give second dose before dinner.

Adverse reactions

CNS: dizziness, drowsiness, headache, weakness

CV: increased CV mortality risk

EENT: blurred vision

GI: nausea, vomiting, diarrhea, constipation, cramps, heartburn, epigastric distress, anorexia

Hematologic: aplastic anemia, agranulocytosis, leukopenia, pancytopenia, thrombocytopenia

Hepatic: cholestatic jaundice, hepatitis

Metabolic: hyponatremia, hypoglycemia

Skin: rash, pruritus, erythema, urticaria, eczema, angioedema, photosensitivity

Other: increased appetite


Drug-drug.Androgens (such as testosterone), chloramphenicol, clofibrate, guanethidine, MAO inhibitors, nonsteroidal anti-inflammatory drugs (except diclofenac), salicylates, sulfonamides, tricyclic antidepressants: increased risk of hypoglycemia

Beta-adrenergic blockers: altered response to glipizide, requiring dosage change; prolonged hypoglycemia (with nonselective beta blockers)

Calcium channel blockers, corticosteroids, estrogens, hydantoins, hormonal contraceptives, isoniazid, nicotinic acid, phenothiazines, phenytoin, rifampin, sympathomimetics, thiazide diuretics, thyroid preparations: decreased hypoglycemic effect

Warfarin: initially increased, then decreased, effects of both drugs

Drug-diagnostic tests.Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, cholesterol: increased values

Glucose, granulocytes, hemoglobin, platelets, white blood cells: decreased values

Drug-herbs.Aloe (oral), bitter melon, burdock, chromium, coenzyme Q10, dandelion, eucalyptus, fenugreek: additive hypoglycemic effects

Glucosamine: impaired glycemic control

Drug-behaviors.Alcohol use: disulfiram-like reaction

Patient monitoring

• Monitor blood glucose level, especially during periods of increased stress.
• Evaluate CBC and renal function tests.
• If patient is ill or has abnormal laboratory values, monitor electrolyte, ketone, glucose, pH, lactate dehydrogenase, and pyruvate levels.
• Monitor cardiovascular status.

Patient teaching

• Advise patient to take daily dose of extended-release tablets with breakfast or immediate-release tablet 30 minutes before breakfast (and second dose, if prescribed, before dinner).
• Advise patient to monitor blood glucose level as instructed by prescriber.
• Tell patient he may need supplemental insulin during times of stress or when he can't maintain adequate oral intake.
• Teach patient how to recognize signs and symptoms of hypoglycemia and hyperglycemia.
• Stress importance of diet and exercise to help control diabetes.
• Instruct patient to wear or carry medical identification describing his condition.
• Advise patient to keep sugar source at hand at all times in case of hypoglycemia.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Tell patient he'll undergo regular blood testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.


/glip·i·zide/ (glip´ĭ-zīd) a sulfonylurea used as a hypoglycemic in the treatment of type 2 diabetes mellitus.


A sulfonylurea drug, C21H27N5O4S, used to treat type 2 diabetes.


an oral antidiabetic drug.
indications It is prescribed as an adjunct to diet and exercise to lower blood glucose levels of patients with type 2 (non-insulin-dependent) diabetes mellitus.
contraindications The dosage may have to be adjusted for patients who are taking drugs such as diuretics that increase blood glucose levels; elderly, debilitated, or malnourished patients are at risk of development of hypoglycemia.
adverse effects Among the most serious adverse effects are nausea, heartburn, and skin allergies.


Glucotrol® Therapeutics A sulfonylurea used to control insulin in type 2 DM. See Diabetes mellitus.


A SULPHONYLUREA drug used to treat maturity onset (Type II) DIABETES. Brand names are Glibenese and Minodiab.

glipizide (glip´izīd),

n brand name: Glucotrol;
drug class: oral antidiabetic (second generation);
action: causes functioning β cells in pancrease to release insulin, leading to a drop in blood glucose levels;
use: stable adult-onset diabetes mellitus (type 2).


a second generation sulfonylurea derivative, used as an oral hypoglycemia agent in the treatment of diabetes mellitus, most commonly in cats.
References in periodicals archive ?
Perrigo Company ("Perrigo"), and generic Glucotrol XL, licensed from Pfizer, as well as revenues from the Company's generic versions of Cardizem(R) CD, Dilacor(R) XR, Glucophage(R), K-Dur(R), Ventolin(R) metered dose inhalers and Naprelan(R), all of which also generated revenues during 2002.
For the 12 months ended September 2003, Glucotrol XL had U.
Pursuant to this settlement, Pfizer and Alza dismissed their lawsuits against Andrx, the parties exchanged mutual releases, and Andrx received the right to either market Glucotrol XL product (or any strength thereof) supplied by Pfizer as an authorized generic and/or to manufacture and market its ANDA product(s) in exchange for a royalty, pursuant to a sublicense for relevant Alza patents.
Net sales for the second quarter of 1995 were slightly lower compared to the corresponding period in 1994, due largely to shipments of launch quantities of Glucotrol XL in the second quarter of 1994.
ALZA's sales and marketing efforts in the United States were expanded in late 1994 when an agreement was reached with Pfizer Inc for ALZA's sales force to co-promote Glucotrol XL (glipizide), a new controlled-release tablet utilizing ALZA's proprietary OROS technology for the 24-hour control of glucose levels in Type II diabetes patients.